02
2021-02
Kintor’s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
Suzhou, Feb.2, 2021--真人直营投注网站 is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China.
28
2021-01
Clinical Trial of Proxalutamide’s Trial of Hospitalized Covid-19 Patients Was Approved in Brazil
Suzhou, Jan 28, 2021--真人直营投注网站 is pleased to announce that the clinical trial of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil. The trial was accepted for accelerated review. We have received support from the Brazilian government in terms of medical resources allocation and expect to start with the patients recruitment over the coming weekend.
17
2021-01
Kintor Presented Results of GT90001 and Nivolumab Combination Therapy at ASCO GI 2021
Suzhou, Jan 17, 2021--真人直营投注网站 is pleased to release the positive data in phase II clinical trial of combination therapy of GT90001 and Nivolumab for the second line therapy of advanced hepatocellular carcinoma(“HCC”) in Taiwan (the “phase II clinical trial”) at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held between January 15 to 17, 2021.
10
2021-01
Kintor’s Preliminary Result of COVID-19 Trial in Female Patients
Suzhou, Jan 10, 2021--真人直营投注网站 (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr. Andy Goren and Dr. Flávio Adsuara Cadegiani, shows promising results in the treatment of COVID-19 female outpatients.
07
2021-01
Suzhou, Jan 10, 2021--真人直营投注网站 (HKEX: 9939) is pleased to announce that the final trial results of Proxalutamide for the treatment of male subjects infected with COVID-19 in Brazil were released. The results showed that Proxalutamide could significantly inhibit the transition of condition of subjects infected with COVID-19 from mild to severe and had good safety for short-term administration (15 days).
30
2020-12
Suzhou, Dec. 30, 2020--真人直营投注网站 is pleased to announce that it took only more than three months for the Company to complete the enrolment of 120 patients required for the Phase II clinical trial for Pyrilutamide (tincture） for the treatment of androgenetic alopecia since its launch in September this year, which is being developed by the Company as a potential first-in-class drug.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn